Company intelligence / Profile preview
GenAhead Bio
- Ownership
- Private
- Development stage
- Other
Overview
GenAhead Bio provides high-efficiency CRISPR/Cas9 genome editing services based on its proprietary SNIPER method and is conducting preclinical research on nucleic acid therapeutics (antisense oligonucleotides and siRNA) delivered via Antibody-Nucleic acid Conjugates, including siRNA delivery to skeletal muscle via anti-transferrin receptor (CD71) antibodies with therapeutic effects in muscular disease models.[1][3][5]
- Therapeutic areas
- NeurologyRare Diseases
- Modalities
- CRISPR-based therapyAntisense oligonucleotideSmall interfering RNARNA therapyAntibodyAntibody-drug conjugateNanoparticle
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on GenAhead Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenAhead Bio.